Emerging Therapies for the Management of Metastatic Castration-Sensitive Prostate Cancer

Released On
January 29, 2021

Expires On
January 29, 2022

Media Type

Completion Time
60 minutes

Hematology-Oncology, Pharmacy, Urology

Oncology, Prostate Cancer

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by AXIS Medical Education and ACCC.

Supported by an educational grant from Astellas and Pfizer, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Nursing Contact Hour
  • Pharmacists — 1.0 Contact Hour

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of medical oncologists, urologic oncologists, urologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with prostate cancer.

Program Overview

Prostate cancer is the second most common cancer, after skin cancer, among men. It is the second leading cause of cancer death in the United States. This year, it is estimated that about 174,650 men in the United States will be diagnosed with prostate cancer and 31,620 men will die from this disease. Androgen deprivation therapy (ADT) aimed at lowering the level of androgens, is the standard of care for men with advanced prostate cancer. Newly diagnosed metastatic disease that has spread to other parts of the body and still responds to testosterone suppression therapy is called metastatic castration-sensitive prostate cancer (mCSPC). Androgen receptor inhibitors are currently being investigated in combination with ADT given the knowledge that deeper androgen signal inhibition results in further improved outcomes in mCSPC. With the recent drug approvals and updates to clinical practice guidelines, several knowledge, competence and performance gaps exist in the optimal management of mCSPC among oncology practitioners. Participants from previous Association of Community Cancer Centers (ACCC) educational programs revealed transitions of care, including communication between the numerous healthcare settings (52%), side effect management (45%), and keeping current on the latest treatment modalities (29%) as among the most commonly encountered challenges for practitioners.

This education activity will provide guidance on the optimal management of mCSPC to oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The educational program will address some of the challenges in optimal sequencing of care in mCSPC and will provide an opportunity to discuss with leading oncology experts and colleagues how new research clinical updates can be translated into new patient care strategies.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe current and emerging treatment options in mCSPC
  • Employ strategies for optimal management of treatment-related adverse events experienced by patients treated for mCSPC
  • Examine solutions for improving coordination and communication within the multidisciplinary cancer care team and with patients/caregivers to improve outcomes for patients with mCSPC


Archana Ajmera, MSN, ANP-BC, AOCNP

Archana Ajmera, MSN, ANP-BC, AOCNP

Advance Practice Provider Supervisor
Division of Hematology/Oncology
Genitourinary Oncology
UCSD Moores Cancer Center

Archana Ajmera, MSN, is a board-certified adult nurse practitioner (ANP-BC) and an advanced oncology certified nurse practitioner (AOCNP). She is currently working as an NP at UC San Diego Health Moores Cancer Center and helps treat people with prostate cancer, renal cell carcinoma, urothelial carcinoma, testicular germ cell tumors and penile carcinoma. Her scope of practice includes collaborating with her physician colleagues in physical evaluations, diagnosis, treatment, symptom management, supportive care, and end of life care. Additionally, she is currently the Advanced Practice Provider Supervisor of Moores Cancer Center at UCSD Health.

Prior to joining UC San Diego Health, Mrs. Ajmera was an oncology nurse practitioner at UC San Francisco, where she cared for adults with hematologic malignancies and bone marrow transplant candidates, as well as women receiving breast cancer treatment. She was also an oncology nurse practitioner at Massachusetts General Hospital in Boston, where she managed the care of women undergoing treatment with surgery and chemotherapy for gynecologic malignancies.

Mrs. Ajmera is also a board-certified women’s health care nurse practitioner (WHNP-BC). She obtained a master’s degree in nursing from Massachusetts General Hospital Institute of Health Professions School of Nursing in Boston. She earned her bachelor’s degree in nutritional science from UC Berkeley. She is a member of the American Society of Clinical Oncology and National Comprehensive Cancer Network (NCCN).

Pedro Barata, MD, MSc

Pedro Barata, MD, MSc

Assistant Professor
Deming Department of Medicine
Division of Hematology/Oncology
Genitourinary Cancers
Tulane University

Dr. Pedro Barata earned his medical degree from the New University of Lisbon in 2009 and completed his medical oncology training in 2016. Subsequently, he was invited to join the genitourinary group at Taussig Cancer Center, where he worked as a clinical fellow in genitourinary malignancies. Dr. Barata then moved to Tulane University to continue his clinical and research work in the GU field. Dr Barata successfully expanded the genitourinary program offered at Tulane Cancer Center and he currently leads the kidney and bladder cancer program at Tulane University with a focus on clinical trials.

Dr. Barata has authored or co-authored more than 60 research publications in high-quality journals, such as Cancer, Annals of Oncology, and CA: Cancer journal Clinicians, with more than 700 scientific citations. In addition, he has presented multiple abstracts at important national and international meetings and has won multiple prestigious awards, including the Scholar-in-Training Award, AACR-NCI-EORTC Triple Meeting (2017) and the Annual Accelerating Anticancer Agent Development and Validation (AAADV) Program Scholarship (2018).

He serves as a reviewer for prestigious peer-reviewed journals, such as JAMA Oncology, ASCO and Journal Global Oncology and is a panel reviewer for Department of Defense Congressionally Directed Medical Research Programs (CDMRP) for genitourinary tumors.

Erik Castle, MD, FACS

Erik Castle, MD, FACS

Professor of Urology
Tulane University

Dr. Erik Castle is a Professor of Urology at Tulane University School of Medicine, specializing in urologic oncology surgery and minimally invasive/robotic surgery.

Dr. Castle's surgical expertise includes robot-assisted radical cystectomy, prostatectomy, retroperitoneal lymph node dissection, and partial nephrectomy. He pioneered robot-assisted radical cystecomy in 2005 and robot-assisted RPLND in 2008 being one of the first surgeons in the world performing these surgeries at that time. Dr. Castle has demonstrated many of these procedures internationally and has published extensively across topics of urologic care and science. He serves on the Early Detection of Prostate Cancer Panel for the National Comprehensive Cancer Network (NCCN).

He earned his medical degree from University of Texas, Southwestern Medical School. He completed Urology Residency at the University of Kansas Medical Center and followed with a Laparoscopic and Reconstructive Urologic Surgery fellowship at Mayo Clinic of Arizona.

Dr. Castle's research focus includes prostate, bladder, testicular, and kidney cancers. He has experience in clinical trials, health sciences research, outcomes research, and basic science research.

Lisa M. Holle, PharmD, BCOP, FHOPA

Lisa M. Holle, PharmD, BCOP, FHOPA

Associate Clinical Professor of Pharmacy Practice
Department of Pharmacy Practice
UConn School of Pharmacy

Dr. Holle completed her Bachelor of Science in Pharmacy and post-baccalaureate Doctor of Pharmacy from the University of Wisconsin–Madison. She completed a specialized oncology residency at UT M.D. Anderson Cancer Center, and is a board-certified oncology pharmacist. Dr. Holle has worked as an oncology pharmacist for over 20 years in a variety of settings including private hospitals, academic medical centers, and medical communications. Currently, Dr. Holle is an Associate Clinical Professor at the UConn School of Pharmacy and Associate Professor at the UConn School of Medicine. Her practice site is at the UConn Health Carole and Ray Neag Comprehensive Cancer Center, where she works in a team-based ambulatory care clinic focusing on genitourinary and gastrointestinal cancers and in another team based-clinic focusing on hematologic malignancies.

Dr. Holle is a Past President of HOPA and a past Secretariat member and Treasurer of the International Society of Oncology Pharmacy Practitioners (ISOPP). She is also an active member in many other professional oncology and pharmacy organizations. Dr. Holle’s clinical research program focuses on numeracy and patient decision-making, oncology quality improvement initiatives, medical marijuana, and oral anticancer therapy management. She has authored numerous articles and chapters on oncology and teaching-related topics.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and ACCC. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.


Credit Designation


AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This application-based activity is approved for 1.0 contact hours of continuing pharmacy education credit JA4008106-9999-21-029-H01-P.


AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Disclosures of Conflicts of Interest

AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.

AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

Archana Ajmera, MSN, ANP-BC, AOCNP

  • Nothing to disclose

Pedro Barata, MD, MSc

  • Consultant: Astellas; Eisai; EMD Serono; Dendreon; Pfizer, Inc.; and Seattle Genetics
  • Contracted Research: AstraZeneca
  • Research Grant: BlueEarth Diagnostics
  • Speaker’s Bureau: Bayer and Caris

Erik Castle, MD, FACS

  • Nothing to disclose

Lisa M. Holle, PharmD, BCOP, FHOPA

  • Nothing to disclose

The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:

Erik Castle, MD

  • Nothing to disclose

Lisa M Holle, PharmD, BCOP, FHOPA

  • Nothing to disclose

Latha Shivakumar, PhD

  • Nothing to disclose

Mary Stanley, MSW, PMP

  • Nothing to disclose

Leigh M. Boehmer, PharmD, BCOP

  • Nothing to disclose

Marilyn Haas, PhD, RN, CNS, ANP-BC

  • Nothing to disclose

Dee Morgillo, MEd., MT(ASCP), CHCP

  • Nothing to disclose

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.

Certificates will be emailed to the participant. For pharmacists, your record will be uploaded to CPE Monitor.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions please contact AXIS at info@axismeded.org.